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ABSTRACT
Background: Fluticasone propionate (FP) DiskusⓇ is generally regarded as an easy to use and efficacious
inhaled device. This study clinically evaluated whether its easy handling and inhalation process were affected
by the aging factor or not, compared with those of the FP DiskhalerⓇ and Beclomethasone dipropionate (BDP).
Methods: Twenty-four elderly patients with stable moderate asthma (12 aged 65―74 years and 12 aged 75
years or older) who were accustomed to using the DiskhalerⓇ were evaluated by measuring the required time
for finishing one-time inhalation with the device, compared with 7 patients aged less than 65. Ten elderly pa-
tients (5 aged 65―74 years, and 5 aged 75 years or older), who used the BDP, were also similarly evaluated
and compared with 8 patients aged less than 65. All subjects then switched to use with the DiskusⓇ and the re-
quired time for finishing one-time inhalation was measured soon after and 2 weeks after the change. The pa-
tients’ usage impressions were also questioned.
Results: The mean required times (seconds) were significantly different between patients aged 75 years or
older, and with patients less than 65 years of age ; 45.8 ± 8.1 vs. 31.8 ± 12.3 (p = 0.046) in the BDP group, and
56.8 ± 25.3 vs. 33.3 ± 18.5 (p = 0.047) in the DiskhalerⓇ, respectively. Soon after changing to the DiskusⓇ,
those times became insignificant in both groups. After 2 weeks, the required time for using the DiskusⓇ was
significantly shortened in all age groups. 50.0% patients in the BDP group and 79.2% in the DiskhalerⓇ group
finally chose the DiskusⓇ.
Conclusions: The FP DiskusⓇ inhalation was not affected by the aging factor and all patients could quickly
get accustomed to using it, suggesting its clinical efficacy for older patients.
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INTRODUCTION
Steroid inhalation, as recommended in the Japanese
guideline for bronchial asthma1 and the Global Initia-
tive for asthma (GINA) 2002,2 currently plays a piv-
otal role in daily asthma therapy. Early and effective
therapy with inhaled corticosteroids results in long-
term remission in the majority of asthmatic patients.3
Many effective inhaled corticosteroids and associated
specialized delivery device systems have been devel-
oped and are clinically distributed world-wide at pre-
sent. There has been an abundant accumulation of
clinical evidence showing the therapeutic efficacy of
the new dry powder type inhaled corticosteroids.4-7
However, I think, the clinical evaluation of the pa-
tients’ view of usage has been insufficient ; in particu-
lar for aged patients. The most distinguishing clinical
factor in elderly patients compared to young and
middle-aged patients is aging itself. This factor often
strongly affects the introduction and continuation of
inhaled corticosteroids for older patients. The aging
changes, such as the decline of understanding, eye-
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Table 1　Patients Characteristics
the FP Diskhaler groupthe BDP group
young and
middle-aged
patients
older patients
young and
middle-aged
patients
older patients
Age range
20―6475―65―74Total20―6475―65―74Total
712122485510Numbers of Patients
46.9 ± 16.078.3 ± 2.871.3 ± 2.374.8 ± 4.443.1 ± 16.379.3 ± 3.869.1 ± 3.274.2 ± 6.3Mean age (yr)
3/49/39/318/66/24/13/27/3Gender (M/F)
6/14/84/8 8/167/10/52/32/8Type of asthma
(Atopic/Non-atopic)
sight and finger movement, often make it difficult for
older patients to handle the inhalation devices
smoothly and naturally. And the most troublesome
clinical problem is that some aged patients are not
aware of their own aging decline . The author has
been interested in the relationship between the aging
factor and the acceptance of inhaled corticosteroids
device systems, and has already investigated and re-
ported on the acceptance of a dry powder type of in-
haled corticosteroid and device system, the Budeson-
ide Turbuhaler TM (BUD-TH), by older asthmatic pa-
tients who were changed to BUD-TH from Beclo-
methasone dipropionate (BDP) with a spacer device
InspirEaseⓇ (Schering-Plough K.K., Osaka, Japan) or
Fluticasone Propionate (FP ) DiskhalerⓇ.8 In that
study, we showed that what was generally considered
to be easy for young and middle-aged patients was
not always easy to handle for aged patients, suggest-
ing the major influence of the aging factor upon the
daily use of an inhalation device．
FP DiskusⓇ, another new type of dry powder in-
haled corticosteroid and a device which is generally
regarded as easy and efficacious, has frequently been
used in recent daily clinical fields. In addition to the
changing of BUD-TH, the change to the FP DiskusⓇ
from other types of inhaled corticosteroids also often
occurs for various therapeutic reasons, requiring the
same kind of clinical evaluation. This study clinically
investigated whether the easy handling of the FP
DiskusⓇ will be affected by the aging factor or not,
and also evaluated the acceptance of the FP DiskusⓇ
by older Japanese patients with bronchial asthma ,
when changed from the previously distributed in-
haled corticosteroids, BDP with a spacer device In-
spirEaseⓇ and the FP DiskhalerⓇ.
METHODS
PATIENT CHARACTERISTICS
Before enrollment in the study, the clinical meaning,
purpose of this study, and the possible disadvantages
including side effects caused by changing to the new
inhaled corticosteroids , were explained in detail to
each patient. Subsequently, 34 elderly Japanese pa-
tients aged 65 or older and 15 aged less than 65 with
stable moderate bronchial asthma (Step 2―3 accord-
ing to Japanese guidelines for the diagnosis and man-
agement of bronchial asthma),1 who could fully un-
derstand this study and who showed their intention
to join this study, were the subject of this study. They
consisted of 24 older asthmatic patients (12 aged 65―
74 years and 12 aged 75 years or older) and 7 patients
aged less than 65 who had become accustomed to us-
ing the DiskhalerⓇ, and 10 older patients (5 aged 65―
74 years and 5 aged 75 years or older) and 8 patients
aged less than 65 who had become accustomed to in-
haling the BDP with InspirEaseⓇ. All subjects had
used their inhaled corticosteroids daily for at least
more than 6 months with a stable asthmatic condi-
tion . Patient characteristics are shown in Table 1.
This study was carried out in accordance with the
principles embodied in the Helsinki Declaration of
1995 (as revised in Edinburgh 2000). Before starting
this study, written informed consent for study partici-
pation was obtained from all the enrolled patients．
PROTOCOL
All of the patients in the BDP group used 800 μgday
of BDP daily and were changed to a half dose of FP
DiskusⓇ in this study. All patients in the FP Disk-
halerⓇ group used 400 μgday of FP DiskhalerⓇ
daily and were changed to the same dose as above of
FP DiskusⓇ in this study. Finally, both groups were
evaluated according to the following terms．
Measurement of Frequency of Explanation Re-
quired at the Introduction of This Device
Before changing to the new device , FP DiskusⓇ,
each patient was carefully instructed on how to use
the device and we investigated the frequency of ex-
planation needed at the time of the introduction until
each of them could fully understand this inhalation
method and perfectly independently perform the suc-
cessive inhalation process . After 2 weeks we con-
firmed whether all of subjects in this study could per-
form inhalation correctly. Each subject was checked
on the detailed inhalation process of the FP DiskusⓇ.
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Fig. 1　Measurement of frequency of explanations required at the intro-
duction of FP Diskus® in each age range. 
Age range
65―74 yr
75―yr
―64 yr
: 1 time
: 2 times
: 3 times
40.0% 60.0%
25.0%
75.0%
40.0%
40.0% 20.0% 25.0%
50.0%
25.0%
0%
100%
0%
100%
the BDP group the FP Diskhaler group
Comparison of Duration of Time Required for
Completing an Inhalation by Each Inhaled De-
vice
The required time for finishing one-time inhalation
with each inhalation device was measured before, the
same day soon after finishing the introductive expla-
nation of the FP DiskusⓇ, and 2 weeks after changing
to the FP DiskusⓇ. The required times for finishing
one inhalation with BDP was defined as the time
from just starting to set the spacer device InspirEase
Ⓡ according to the starting sign, to the time finishing
one inhalation, just before starting the next expira-
tory breath. The required time for finishing one inha-
lation with the FP DiskhalerⓇ was defined as the
time from starting to set a sheet of RotadiskⓇ accord-
ing to the starting sign to the time finishing one inha-
lation, just before starting the next expiratory breath.
The time with the FP DiskusⓇ was also defined as
the time from starting to slide the cover according to
the starting sign, to the time to finish one inhalation,
just before starting the next expiratory breath. Each
required time was measured three times and then we
calculated the average . In addition , the required
times were measured by the same doctor throughout
this study．
Patients’ Questionnaires Concerning Their Ac-
ceptance and Impressions of the FP DiskusⓇ
The following simple patient questionnaires , which
were easy even for aged patients to answer, concern-
ing their impressions of using the FP DiskusⓇ, were
given after 2 weeks.
Q1 : Do you feel it is easy or not easy to use the FP
DiskusⓇ daily , compared with your previous de-
vice？
Q2 : Which do you wish to continue to use, the FP
DiskusⓇ or your previous device？
Q3 : If you notice anything when you use the FP
DiskusⓇ for these 2 weeks, please let me know．
Side Effects
The author questioned all of the patients in detail for
the occurrence of side effects during the 2 weeks af-
ter changing to the FP DiskusⓇ or not．
Comparison of Drug Compliance after 8 Weeks
Using each patient’s asthma diary and the number on
the counter of FP DiskusⓇ, drug compliance was also
investigated and compared 8 weeks before and after
changing to the FP DiskusⓇ.
Comparison of Daily Peak Expiratory Flow (PEF)
and Pulmonary Function Test
8 weeks after the start, the improvement of daily peak
expiratory flow (PEF) checked in accordance with
each patient’s asthma dairy and pulmonary function
tests was also measured．
STATISTICAL ANALYSIS
All data are expressed as mean ± standard deviation.
Each comparison in Figure 2 and Figure 3 was made
using the unpaired student t test and each compari-
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Fig. 2 The comparison of the required inhalation time among each age range groups in the BDP 
group (A) and the FP Diskhaler® group (B). Statistical significance: ＊P < 0.05. N.S. represented as no 
statistical significance compared with the time of patient group aged less than 65.
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Fig. 3 The comparison of the required inhalation time soon after changing to the Diskus® in the pre-
BDP group (A) and the pre-FP Diskhaler® group (B). N.S. represented as no statistical significance 
compared with the time of patient group aged less than 65.
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son in Figure 4 was done by using the paired student
t test. P values of less than 0.05 were considered sig-
nificant.
RESULTS
Patients in both groups tolerated the new medication
well and no unexpected adverse events were hap-
pened during this study.
MEASUREMENT OF FREQUENCY OF EXPLANA-
TION REQUIRED AT THE INTRODUCTION OF
THIS DEVICE (Fig. 1)
As shown in Figure 1, within the age range of 65―74
years old, 2 patients (40.0%) in the BDP group and 3
patients ( 25.0% ) in the FP DiskhalerⓇ group re-
quired more than 2 explanations , until they could
fully understood this inhalation method and perfectly
performed the successive inhaled process by them-
selves. However, no more than a total of 3 explana-
tions in both groups were required. In addition, 2 pa-
tients (40.0%) aged 75 years and older in the BDP
group, required 2 explanations and 3 explanations re-
spectively at the introduction of FP DiskusⓇ, 6 pa-
tients (3 (25.0%) and 3 (25.0%)) in the FP DiskhalerⓇ
group needed 2 and 3 explanations, respectively. In
contrast , all young and middle-aged patients could
adequately understand and perfectly perform the suc-
cessive inhaled process of FP DiskusⓇ after only one
careful explanation at the introduction．
After 2 weeks, we confirmed in detail whether all
the patients in this study could properly perform the
inhalation method or not. There were no serious mis-
414 Allergology International Vol 54, No3, 2005 www.js-allergol.gr.jp
Ohbayashi H
Fig. 4 The comparison of the required inhalation time between soon after introduction and 2 weeks 
later in each age range groups in the pre-BDP group (A) and the pre-FP Diskhaler® group (B). Statisti-
cal significance: ＊P < 0.05 and ＊＊P < 0.01. 
0
10
20
30
40
50
60
―64  yr 65―74 yr 75―yr
(A)
T
he
 r
eq
ui
re
d 
in
ha
la
tio
n 
tim
e 
(s
ec
)
＊
0
10
20
30
40
50
60
―64  yr 65―74 yr 75―yr
(B)
T
he
 r
eq
ui
re
d 
in
ha
la
tio
n 
tim
e 
(s
ec
)
＊＊ ＊＊ ＊＊
takes, which affected the successive inhaled process
itself , in either group . However , 9 older patients
(26.5%)(4 patients in the BDP group and 5 in the FP
DiskhalerⓇ group) were found to unnecessarily re-
turn the lever after an inhalation . Furthermore , 3
older patients (8.8%)(these 3 patients were all in the
BDP group) took a breath while attaching the device
to the mouth. Even in the young and middle-aged
group, 2 patients (13.3%)(1 patient in the BDP group
and 1 in the FP DiskhalerⓇ group) also unnecessarily
returned the lever after an inhalation. Those minor
mistakes could be easily corrected at that time. At the
end of this study, all older patients enrolled in the
study, as well as young and middle-aged patients ,
could use the DiskusⓇ smoothly．
MEASUREMENT OF THE TIME REQUIRED FOR
COMPLETING AN INHALATION BY EACH INHA-
LATION DEVICE (Figs. 2―4)
As shown in Figures 2 (A) and (B), there were the
significant differences in the required inhalation time
between patients aged less than 65 and ones aged 75
and over, in the BDP group (p = 0.046) and the FP
DiskhalerⓇ group (p = 0.047), respectively. On the
other hand , soon after changing to the DiskusⓇ,
these significant differences disappeared in the pre-
BDP group (p = 0.053)(Fig. 3(A)), and in the pre-FP
DiskhalerⓇ group (p = 0.051)(Fig . 3(B )). Further-
more , after 2 weeks , the required time with the
DiskusⓇ was significantly shortened in the patient
group aged 75 and over in the pre-BDP group (Fig. 4
(A)). Furthermore, the required inhalation time in
any age range of patients in the pre-FP DiskhalerⓇ
group were significantly shortened after 2 weeks ,
compared with the time soon after introduction (Fig.
4(B)).
RESULTS OF THE PATIENT QUESTIONNAIRES
Results of the patient questionnaires after 2 weeks
are shown as follows.
Q1: Do you feel it is easy or not easy to use FP
DiskusⓇ daily, compared with your previous device?
80.0% of older patients in the BDP group and 91.7%
in the FP DiskhalerⓇ group answered that the handle
of FP DiskusⓇ was easier compared with their previ-
ous inhalation device . The rest of the subjects re-
sponded that the difficulty in handling of the FP
DiskusⓇ was almost the same compared with their
previously used devices. In contrast, all of young and
middle-aged patients answered that FP DiskusⓇ was
so much easier to use, compared with their previous
device．
Q2: Which do you wish to continue to use , FP
DiskusⓇ or your previous device?
50.0% of aged patients chose to continue FP
DiskusⓇ inhalation in the BDP group , while 30%
chose the previously used BDP and 20% answered
that any device will do. On the other hand, 79.2% of
aged patients in the FP DiskhalerⓇ group finally
chose to continue FP DiskusⓇ inhalation, while 12.5%
chose the previously used device and the rest an-
swered that any will do. In contrast, all in the young
and middle-aged group finally chose FP DiskusⓇ.
Q3: If you notice anything when you use FP DiskusⓇ
for these 2 weeks, please let me know
5 patients answered that the counter system in FP
DiskusⓇ, which decreased the number one by one
per inhalation, was so convenient due to the fact that
they could confirm whether they had actually fin-
ished their daily inhalations. However, 3 of the pa-
tients pointed out that that the size of counter num-
ber was too small for aged patients with presbyopia
and should be made bigger.
Allergology International Vol 54, No3, 2005 www.js-allergol.gr.jp 415
The Acceptance of FP Diskus by Older Patients
Fig. 5 The comparison of drug compliance between 8 weeks before and after changing to the FP 
Diskus®.
8 weeks before changing to the FP Diskus® 8 weeks after changing to the FP Diskus®
8 weeks before changing to the FP Diskus® 8 weeks after changing to the FP Diskus®
: 90―100 % of the performance in daily inhalation
: 75―89 % of the performance in daily inhalation 
drug compliance
Age rage
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Age rage
75yr―
65―74 yr
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    25.0
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14.3
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SIDE EFFECTS
A hoarse voice and abnormal dry feeling in the mouth
after FP DiskusⓇ inhalation occurred in 11 patients
out of the 34 patients (32.4%) as side effects, but in
none of the young and middle-aged patients . How-
ever, each side effect was so mild that they did not
need to discontinue use of the FP DiskusⓇ inhala-
tion. Most of the side effects were diminished or dis-
appeared by gargling soon after one inhalation or by
controlling each patient’s inhalation speed．
RESULT OF DAILY DRUG COMPLIANCE (Fig. 5)
Drug compliance was also investigated 8 weeks be-
fore and after changing to the FP DiskusⓇ. 8 weeks
before changing to the FP DiskusⓇ, 7 elderly patients
in the BDP group (3 patients aged 65―74 years and 4
ones aged 75 years or older) and 17 in the FP Disk-
halerⓇ group (7 patients aged 65―74 years and 10
ones aged 75 years or older) had some inconsistency
between the daily inhalation times as noted in their
asthma diary and the actual residual doses of inhaled
corticosteroids. However, 8 weeks after changing to
the FP DiskusⓇ, almost all the older patients’ daily
drug compliance had improved (Fig. 5). The sum of
the daily regular inhalation times in patient’s asthma
diary were almost the same as the number indicated
on the counter of the DiskusⓇ, suggesting good daily
drug compliance.
RESULTS OF CHANGES IN DAILY PEF AND
PULMONARY FUNCTION TEST
As for daily PEF, there was no statistical significance
found between before changing to the FP DiskusⓇ
and 8 weeks after changing to the FP DiskusⓇ in
both groups in this study. In the BDP group , the
mean PEF values (L/min) of the patients aged 75
years or older, 65―74 years, and less than 65 years
old were 279.0 ± 112.2 vs. 281.6 ± 112.7, 281.7 ± 86.3
vs. 282.2 ± 92.4, and 441.0 ± 49.0 vs. 449.6 ± 54.0, be-
fore and after changing to FP DiskusⓇ, respectively.
On the other hand, those (L/min) in the DiskhalerⓇ
group were 224.6 ± 105.1 vs. 225.5 ± 107.3, 302.5 ±
81.5 vs. 302.1 ± 82.2, and 394.4 ± 121.7 vs. 392.3 ±
119.9, before and after changing to the FP DiskusⓇ,
respectively. As for the pulmonary function test, there
was also no statistical significance found between be-
fore changing to the FP DiskusⓇ and 8 weeks after
changing to FP DiskusⓇ in both groups in this study
(data not shown)．
DISCUSSION
In order to directly send inhaled corticosteroids into
the asthmatic inflammatory airways and to display its
therapeutic effects fully, an inhalation device plays a
pivotal role in inhaled corticosteroid therapy. Many
inhalation devices have been developed and are used
in the present daily clinical field, and most of them
may tend to focus upon how much drug can be deliv-
ered effectively into airways as possible . 9,10 Even
though the inhaled corticosteroid itself has a power-
ful effect upon asthmatic inflammation and its deliv-
ery is very good, patient training and compliance will
continue to be important factors in the success , or
failure, of inhaled therapy.11 Moreover, the patient’s
poor acceptance of the device possibly causes insuffi-
cient inhalation, spoiling its therapeutic usefulness .
As shown in our previous study,8 although a patient’s
poor inhalation technique and poor acceptance of the
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device can be caused by various individual reasons,
the aging factor, including cognitive function, often
has a remarkable effect upon its therapeutic useful-
ness . 12,13 What is generally easy for young and
middle-aged patients to handle is not always easy for
older patients. The aging factor strongly influences
both the smoothness in handling the device and the
ease of getting accustomed to it, which are closely re-
lated to the required inhalation time．
In this study, by means of measuring the required
inhalation time comparing young and middle-aged pa-
tients , the author showed that the inhalation time
with the DiskusⓇ was not strongly affected by the ag-
ing factor, compared with the other two devices BDP
with a spacer device InspirEaseⓇ and FP DiskhalerⓇ.
Generally, when there are many processes in han-
dling the device leading to one complete inhalation, it
will , of course, take longer to finish the inhalation
process. Although times vary with each inhaled de-
vices, the relatively longer required inhalation time
does not detract from the therapeutic benefit to the
patients. The comparison of the required inhalation
time among different devices themselves is not of any
direct significance , but also the shorter inhalation
time does not always signify the clinical superiority of
the device. However, the comparison of the required
inhalation times using the same device is another
story. When it takes a significantly longer time for
older patients to finish the inhalation process with the
device, compared to that of young and middle-aged
patients when using the same device, important clini-
cal meaning is highlighted, particularly in that diffi-
cult and time-wasting handling for older patients
within the course of inhalation process with this de-
vice exists actually requires a therapeutic approach.
As the aim of this study is to make it clear that for
older patients there is a difficulty handling the device
due to the aging factor , the comparison of the re-
quired inhalation time when using the same device
between older patients and young and middle-aged
ones is clinically important. And, as another therapeu-
tic aim is to correct the wrong handling which dis-
turbed the daily smooth inhalation and to acquire a
comfortable process for older patients , the time-
course comparison when using the same device will
be also important to evaluate how the patients got ac-
customed to handling this device．
As shown in this study (Figs. 2(A), (B)), despite
the fact that the patients who were the subject of this
study had already been using their devices more than
6 months, there were significant differences in the re-
quired inhaled time, for using both the BDP with In-
spirEaseⓇ and the FP DiskhalerⓇ, between young
and middle-aged patients and older ones, in particular
those aged 75 and more, suggesting the existence of
difficult and time-wasting handling in the inhalation
process with the BDP and the FP DiskhalerⓇ for
older patients. In contrast, soon after changing from
these previously used devices to the DiskusⓇ, those
significant differences, in the inhalation time between
young and middle-aged patients and older patients ,
disappeared (Figs. 3(A), (B)), meaning there was
less time-wasted and a less complicated handling
process when using the DiskusⓇ, for older patients.
Furthermore, all the patients in this study, older as
well as the young and middle-aged ones, learned the
use of FP DiskusⓇ correctly and performed its hand-
ing smoothly by the end of the 2 week-long study,
which was accompanied by significant reductions in
the required inhalation time (Figs. 4(A), (B)). This
suggests it is easy to get accustomed to handling the
device. A previous study by Boulet et al. reported that
84% of 376 subjects ( age range:12―75 years) could
use the DiskusⓇ after the first explanation, while 73%
did in the DiskhalerⓇ group, and they also reported
that patients preferred DiskusⓇ to DiskhalerⓇ (73%
vs. 15%).14 Their data is not inconsistent with the re-
sults of this study.
Moreover, all in the young and middle-aged group
answered that handling the FP DiskusⓇ was easy and
also finally chose the FP DiskusⓇ. In contrast , de-
spite more than 80% of older patients in this study an-
swering that the handling of the FP DiskusⓇ was eas-
ier compared with their previous inhalation devices,
50.0% of aged patients in the BDP group and 79.2% of
those in the FP DiskhalerⓇ group finally chose to
continue FP DiskusⓇ inhalation, while the rest did
not, suggesting the possibility of the existence of an-
other clinically influenced factor such as devotion to
the previous device because they have already gotten
accustomed to its handling．
In this study, the author also showed that the daily
drug compliance of most patients improved after
changing from a previously used device to FP
DiskusⓇ (Fig. 5). The enhancement of patient drug
compliance in this study may be partly due to the
ease of getting accustomed to handling the device ,
and partly to the counter system which decreases the
number one by one per inhalation. Each patient can
know the exact number of doses left and can recon-
firm, whether he has already taken the daily dose, by
the indicated number on the counter. This offers the
elderly patients’ relief, thereby ensuring good compli-
ance. Furthermore, the counter system is also con-
venient for the physician as she confirm whether the
patient is regularly using the inhaled drug or not ac-
cording to his therapeutic plan , by checking the
counter number on the device which the patients
bring into the clinic. However, as some patients actu-
ally pointed out, the size of counter number is too
small for older patients with presbyopia. When this
point is improved, this device will be more acceptable
for older patients and its therapeutic usefulness will
be further enhanced.
In summary, this study pointed out the clinical use-
fulness of FP DiskusⓇ, as its handling was not signifi-
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cantly affected by the aging factor, along with a rec-
ommendation to its therapeutic use as a sophisticated
device for older asthmatic patients.
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